Allergy and asthma proceedings最新文献

{"title":"Body weight trajectory of non-obese asthmatics: Relationship with inhaled corticosteroids maintenance therapy.","authors":"Monique Olivia Burch, Daniel Gimenez Rocha, Leticia Belleze, Marcos Jose Oliveira Da Silva, Renata Pletsch Assuncao, Daniel Antunes, Ronei Luciano Mamoni, Eduardo Vieira Ponte","doi":"10.2500/aap.2025.46.250041","DOIUrl":"10.2500/aap.2025.46.250041","url":null,"abstract":"<p><p><b>Background:</b> It is unclear whether the continuous use of a high dose of inhaled corticosteroids (ICS) could contribute to an unfavorable trajectory in body weight. <b>Objectives:</b> The objective was to evaluate whether a high dose of ICS used continuously for maintenance therapy increases the risk of an unfavorable body weight trajectory in individuals with asthma and who are not obese. <b>Methods:</b> We screened consecutive individuals with chronic respiratory symptoms suggestive of asthma who underwent a medical consultation in any of the 42 public health facilities in the municipality of Jundiaí, Brazil. We included individuals with proven asthma who were ≥ 20 years of age and who had a body mass index (BMI) < 30 kg/m² on the day of screening for the study. Individuals participated in two study visits 12 months apart, named V₁ and V₂. Between study visits, individuals had one intermediate consultation with their referring physician. <b>Results:</b> Ninety-nine individuals used a high dose of ICS during the study and 294 used a low-medium dose. The individual with asthma and no obesity and who used a high dose of ICS had a similar risk of having obesity at V₂ compared with those who used a low-medium dose (adjusted odds ratio 1.18 [95% confidence interval, 0.46-3.04]). The probability of gaining weight was similar between the two groups. <b>Conclusion:</b> The use of a high dose of ICS for 1 year does not increase the risk of obesity among individuals with asthma and who are not obese, nor is it associated with an unfavorable body weight trajectory compared with individuals with asthma who were using a low-medium dose of ICS. This information may help reduce fears about using ICS.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 4","pages":"296-303"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed pressure urticaria successfully treated with omalizumab: A tertiary-level health-care center experience.","authors":"Mehmet Erdem Cakmak, Nida Oztop","doi":"10.2500/aap.2025.46.250031","DOIUrl":"10.2500/aap.2025.46.250031","url":null,"abstract":"<p><p><b>Background:</b> Delayed pressure urticaria (DpU) is a subtype of inducible urticaria characterized by painful erythematous swellings that appear after pressure is applied to the skin. <b>Objectives:</b> The aim of this study was to evaluate the efficacy of omalizumab treatment in patients with DpU and the effect of omalizumab treatment on disease control. <b>Methods:</b> This retrospective observational study included a total of 78 patients with chronic spontaneous urticaria (CSU) or DpU who received omalizumab treatment. At 6 months after the initiation of omalizumab treatment, the effects of the treatment on the the urticaria control test (UCT) and the Dermatology Quality of Life questionnaire (DLQI) score and the effects on pressure urticaria were evaluated. The effect of omalizumab on pressure urticaria was determined by performing a pressure provocation test. <b>Results:</b> At the end of the 6th month of omalizumab treatment, the increase in UCT scores was statistically significant in all the patients, in the patients with CSU, and in the patients with CSU plus DpU (p < 0.001, p = 0.025, and p < 0.001, respectively). At the end of the 6th month of omalizumab treatment, the improvement in DLQI scores was statistically significant in all the patients, in patients with CSU, and in patients with CSU plus DpU (p < 0.001, p = 0.002, and p < 0.001, respectively). After the pressure provocation test, no urticarial wheals were observed in the area where pressure had been applied in any patient within 6 hours. <b>Conclusion:</b> The findings of the current study provide evidence that omalizumab treatment may be effective in patients with DpU.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 4","pages":"323-327"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding horizons of omalizumab: New frontiers in asthma and beyond.","authors":"Joseph A Bellanti, Russell A Settipane","doi":"10.2500/aap.2025.46.250042","DOIUrl":"10.2500/aap.2025.46.250042","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 4","pages":"271-273"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of direct oral provocation test results in mild cutaneous reactions to cephalosporins in children.","authors":"Fatma Nur Kuzucu, Cankat Genis, Ahmet Selmanoglu, Kezban Ipek Demir, Zeynep Sengul Emeksiz, Emine Dibek Misirlioglu","doi":"10.2500/aap.2025.46.250011","DOIUrl":"10.2500/aap.2025.46.250011","url":null,"abstract":"<p><p><b>Background:</b> Cephalosporins are beta-lactam antibiotics commonly used in children and are the second most common cause of drug hypersensitivity reactions after penicillins. Antibiotic allergy is diagnosed by tests such as prick and intradermal skin tests and the drug provocation test (DPT). Skin tests can be challenging for both patients and clinicians. In appropriate cases, omitting these tests in favour of direct DPT may help to avoid diagnostic delays. <b>Objective:</b> Our study aimed to evaluate the results of direct DPT in children with a history of mild cutaneous reactions to cephalosporins. <b>Methods:</b> Between 2019 and 2024, pediatric patients with a documented history of mild cutaneous reactions to cephalosporins who underwent direct DPT without prior prick or intradermal skin testing were included in this study conducted at our clinic. Patients with systemic manifestations beyond cutaneous reactions at the time of the index reaction were excluded from the study. <b>Results:</b> The study included 128 patients who underwent direct DPT with cephalosporins. The most commonly suspected drugs were cefixime (45.3%), cefdinir (25.8%) and cefuroxime (18%). While 96.1% did not react, cephalosporin allergy was confirmed in 3.9% but all reactions were limited to skin involvement and none more severe than the index reaction. <b>Conclusion:</b> In our study, direct DPT ruled out suspected allergy in 96.1% of patients with a history of mild skin reactions to cephalosporins. In conclusion, direct oral DPT was found to be a safe and feasible approach for patients with isolated mild skin reactions, effectively bypassing the need for skin testing.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"235-239"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New England Society of Allergy Spring Meeting Abstracts presented March 28, 2025, Worcester, MA.","authors":"","doi":"10.2500/aap.2025.46.250033","DOIUrl":"10.2500/aap.2025.46.250033","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"267-268"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab.","authors":"Petra Staubach, Timothy J Craig, Tomoo Fukuda, Emel Aygoren-Pursun, Roman Hakl, Julia Braverman, John-Philip Lawo, Maressa Pollen, Chiara Nenci, Philip H Li, Henriette Farkas","doi":"10.2500/aap.2025.46.250026","DOIUrl":"10.2500/aap.2025.46.250026","url":null,"abstract":"<p><p><b>Background:</b> Hereditary angioedema (HAE) is associated with substantial health-related quality of life (HRQoL) impairments. Complete disease control and life normalization are key treatment goals. In previous studies, garadacimab prevented HAE attacks with a favorable safety profile and HRQoL improvements. <b>Objective:</b> HRQoL was evaluated in patients with HAE receiving garadacimab stratified by attack-free status. <b>Methods:</b> In the pivotal phase III study (NCT04656418), 39 patients received garadacimab 200 mg subcutaneously once monthly and 25 volume-matched placebo. In the phase III open-label extension (OLE), 90 patients in the garadacimab-naive group (received placebo in previous studies or newly enrolled) and 71 patients in the previous garadacimab exposure group (received garadacimab in previous studies) received garadacimab (NCT04739059). Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status. <b>Results:</b> In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free. In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20). In the phase III OLE study, the mean AE-QoL total score for patients who were garadacimab naive decreased from 46.2 (day 1) to 8.6 (month 12) for attack-free patients (n = 34) and from 54.5 to 23.5 for patients with one or more attacks (n = 30). For the previous garadacimab exposure group, AE-QoL improvements were maintained from previous studies, regardless of attack-free status. <b>Conclusion:</b> Garadacimab was associated with HRQoL improvement versus run-in in all groups. After garadacimab exposure in previous studies, improvements were maintained in the phase III OLE study. Attack-free patients had the greatest HRQoL improvements, bringing them closer to complete disease control and life normalization.Clinical trials NCT04656418, NCT04739059, <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://www.clinicaltrials.gov\">www.clinicaltrials.gov</ext-link>.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"200-208"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing social media conversations to gain insights into the experiences of patients with hereditary angioedema.","authors":"Julia Braverman, Darcy Ellis, Simona Gavata-Steiger, Angeline Babitha Dhas, Revanth Muthu, Quazi S Ataher","doi":"10.2500/aap.2025.46.250028","DOIUrl":"10.2500/aap.2025.46.250028","url":null,"abstract":"<p><p><b>Background:</b> Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent, unpredictable, painful, and potentially life-threatening angioedema attacks, which substantially impair patients' quality of life. Gathering patients' perspectives is important to understand lived experiences, the patient journey, and preferences to determine optimal HAE management. Social media platforms have become important mediums through which patient and carer groups share experiences and advice. <b>Objective:</b> We conducted the first social media listening (SML) study in an HAE setting to identify and characterize the experiences of patients with HAE to better understand disease and treatment burden and their unmet needs. <b>Methods:</b> This was a retrospective analysis of social media content that relates to the experience of individuals with HAE from January 2018 to October 2023. We used keyword-based searches of social media platforms to identify posts that relate to burdens, unmet needs, and other themes shared by patients, caregivers, or health-care professionals. After anonymization and removal of duplicates, content was extracted and categorized by subject matter experts for qualitative and quantitative analysis according to themes. <b>Results:</b> Of 6,012 posts collected, 892 were identified as relevant patient-mentioned posts. Of these, 459 posts related to burden; the most common topic was disease burden and discussed symptoms such as persistent swelling, painful attacks, and frequent attacks. Other burden-related topics included health service, medication, and injections. Unmet needs were discussed in 270 posts; the most common were treatment-related needs such as insurance denials, inadequate medication availability, and treatment costs. Other unmet needs related to education, health service, and diagnosis. <b>Conclusion:</b> Evaluation of the lived experience of patients with HAE and their caregivers <i>via</i> SML can be a valuable tool to aid optimizing HAE management. Our findings add to existing evidence that the disease burden is still a considerable issue for patients with HAE, who continue to have unmet treatment needs.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":" ","pages":"218-226"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of ciprofloxacin hypersensitivity improves by incorporating MRGPRX2 in basophil activation test.","authors":"Osman Ozan Yegit, Metin Yusuf Gelmez, Semra Demir, Nilgun Akdeniz, Ilkim Deniz Toprak, Pelin Karadag, Ali Can, Derya Unal, Gunnur Deniz, Asli Gelincik","doi":"10.2500/aap.2025.46.250024","DOIUrl":"10.2500/aap.2025.46.250024","url":null,"abstract":"<p><p><b>Background:</b> Immediate hypersensitivity reactions (IHR) to ciprofloxacin can be caused by Mas-related G-protein coupled receptor X2 (MRGPRX2) as well as immunoglobulin E (IgE)-dependent mechanisms. When considering the complexity of the Patho mechanism, there are doubts with regard to the adequacy of conventional basophil activation test (BAT) in diagnosing fluoroquinolone-induced IHR. Our aim was to present a BAT method that relies on specifically evaluating the basophils expressing MRGPRX2 to increase the diagnosis rate of ciprofloxacin-induced MRGPRX2-mediated IHR. <b>Methods:</b> CD63 and MRGPRX2 expressions were analyzed with and without ciprofloxacin stimulation on basophils from patients and healthy controls by using flow cytometry. The net percentage of upregulation (net%) of MRGPRX2 and CD63 on basophils were statistically analyzed. <b>Results:</b> Fourteen patients with confirmed IHR to ciprofloxacin and age- and gender-matched 12 healthy controls were analyzed. The median (interquartile range) age of the patients was 39.5 years (33.5-51.5 years) and 92.9% were women. The median (interquartile range) net% expression of CD63 on basophils, MRGPRX2 on basophils, and CD63 on MRGPRX2⁺ basophils after ciprofloxacin stimulation was all higher in patients (18.1 [5.8-25.3], 3.7 [3.0-5.4], and 13.9 [7.8-28.8], respectively) compared with healthy controls (6.6 [3.8-11.4], 2.4 [0.6-3.7], and 1.3 [0.4-8.9], respectively) (p = 0.027, p = 0.042, and p = 0.001, respectively). Receiver operating characteristic analysis showed that the net% of CD63 expression on MRGPRX2⁺ basophils had a greater area under the curve to predict ciprofloxacin IHR than did the net% of CD63 expression on basophils. A net% > 10.3% of CD63 expression on basophils showed a sensitivity of 71.4% and a specificity of 75.0%, whereas a net% > 3.9% of theCD63 expression on MRGPRX2⁺ basophils showed a sensitivity of 100% and a specificity of 75.0%. The proposed method diagnosed four more patients compared with the conventional BAT. <b>Conclusion:</b> Analysis of our data indicated that the determination of MRGPRX2 together with CD63 in basophils improves the <i>in vitro</i> diagnosis of ciprofloxacin IHR with a better sensitivity compared with conventional BAT.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"247-256"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.","authors":"Mar Guilarte, William R Lumry, Markus Magerl, Inmaculada Martinez Saguer, Avner Reshef, Marta Sobotkova, Julia Braverman, John-Philip Lawo, Lolis Wieman, Chiara Nenci, Constance H Katelaris","doi":"10.2500/aap.2025.46.250027","DOIUrl":"10.2500/aap.2025.46.250027","url":null,"abstract":"<p><p><b>Background:</b> Hereditary angioedema (HAE) attacks substantially impair health-related quality of life (HRQoL). Current World Allergy Organization and the European Academy of Allergy and Clinical Immunology guidelines goals include complete control and normalization of patients' lives. Garadacimab (anti-activated factor XII monoclonal antibody) reduced the mean attack rate after first administration in the pivotal phase III (VANGUARD; NCT04656418) and ongoing long-term phase III open-label extension (OLE) (NCT04739059) studies. <b>Objective:</b> To report exploratory HRQoL data from the interim analysis of the phase III OLE study (data cutoff February 13, 2023). <b>Methods:</b> Patients ages ≥12 years and with HAE received garadacimab 200 mg subcutaneously once monthly in the OLE study. The patient population comprised patients who were garadacimab naive (received placebo in the previous phase III study and newly enrolled patients) and patients who received garadacimab in previous phase II/III studies. The Angioedema Quality of Life (AE-QoL) questionnaire, Treatment Satisfaction Questionnaire for Medication version II (TSQM II), and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire were administered at baseline and every 3 months during the OLE study. AE-QoL and TSQM II scores were evaluated in comparison with minimal clinically important differences (MCID). <b>Results:</b> Overall, 90 patients who were garadacimab naive and 71 patients with previous garadacimab exposure received garadacimab in the phase III OLE study. The mean ± standard deviation AE-QoL total score improved by 34.2 ± 18.8 points in patients who were garadacimab naive and by 2.3 ± 13.1 points further to the reduction experienced in patients with previous garadacimab exposure. The AE-QoL MCID was met by 92.1% of patients who were garadacimab naive; 81.6% of patients with previous garadacimab exposure experienced stable AE-QoL scores or further improvements per MCID. TSQM II scores were improved from day 1 with garadacimab and sustained to month 12. Improvements in WPAI:GH scores were consistent with AE-QoL and TSQM II. <b>Conclusion:</b> Garadacimab elicited clinically meaningful long-term improvements in HRQoL, work productivity, and treatment satisfaction in patients with HAE, which brought them closer to complete disease control and normalization of life.Clinical trial NCT04739059, <ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://clinicaltrials.gov\">clinicaltrials.gov</ext-link>.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"192-199"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value-based care in allergy-immunology: Beyond the quality-adjusted life year.","authors":"Jason Sanders, Matthew Greenhawt, John Oppenheimer, Aikaterini Anagnostou, Marcus S Shaker","doi":"10.2500/aap.2025.46.250015","DOIUrl":"10.2500/aap.2025.46.250015","url":null,"abstract":"<p><p><b>Background:</b> Value-based health care in the field of allergy/immunology must be informed by multiple factors, including costs (direct and indirect), outcomes, and the patient experience. <b>Objective:</b> We review features that define value-based health care and discuss a perspective that considers cost-effective care beyond the quality-adjusted life year (QALY). <b>Methods:</b> A narrative review and synthesis of the literature was leveraged to advance an understanding of health-care delivery that considers shared decision-making, health-economic outcomes, and the patient experience. <b>Results:</b> The patient and family experience of health and wellness must be considered carefully when interpreting health-economic evaluations. Health-state utilities consider trade-offs for wellness under conditions of risk and are used to inform QALYs for a myriad of disease states. Cost-effectiveness of medical therapies relates to trade-offs that are considered for populations, but these metrics can be translated holistically to inform health-care decisions for patients if considered contextually. In the case of food allergy, omalizumab would likely not be cost-effective on an individual level (incremental cost-effectiveness ratio, $573,698/QALY), but for those individuals with a high utility impairment, or, if considered from the perspective of a family unit, may be a more attractive therapy from a health-economic point of view. <b>Conclusion:</b> The balance between health and disease is such that there is always more disease than can be treated at any given moment, and both money and time can only be spent once. Because choice is inevitable, health-economic analysis can help inform clinical care. Still, translating population-level cost-effectiveness to individuals is challenging and decisions must be tailored to each patient and context.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 3","pages":"165-167"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}